The study delves into the uncertain territory of neoadjuvant therapy (NAT) for ampullary (AA) and duodenal adenocarcinoma (DA). Analyzing 15 retrospective studies, no clear survival differences were found between NAT and upfront surgery. While some studies hinted at benefits like increased pathologic response, overall evidence supporting NAT for AA and DA is weak. The research urges for more robust data, emphasizing the need to better comprehend the multidisciplinary management of these periampullary malignancies.
Review by Zhang C, Lizalek JM (…) Reames BN et 3 al. in Ann Surg Oncol
© 2023. Society of Surgical Oncology.